Drug Profile

Maridebart cafraglutide - Amgen

Alternative Names: AMG-133; MariTide

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amgen
Class Antihyperglycaemics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Obesity therapies
Mechanism of Action Gastric inhibitory polypeptide receptor antagonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Obesity; Type 2 diabetes mellitus

Most Recent Events

23 May 2025 Amgen plans phase-III MARITIME-3-J trial for Obesity (In adults, In the elderly) in June 2025 (SC) (NCT06987695)
17 Mar 2025 Phase-III clinical trials in Obesity in USA (SC) (NCT06858878)
17 Mar 2025 Phase-III clinical trials in Type 2 diabetes mellitus in USA (SC) (NCT06858878)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com